News & Updates

Heart failure carries tenfold increase in kidney disease risk in T2D

Among individuals with type 2 diabetes (T2D), heart failure is strongly linked to worsening kidney function, such that the risk of end-stage kidney disease (ESKD) soars tenfold following heart failure events, according to a Singapore study.

Does paternal use of metformin up risk for congenital malformations?

Use of metformin monotherapy by fathers during the sperm development period prior to conception does not appear to contribute to an increased risk of major congenital malformations (MCMs) in newborns, reveals a study.

Original New Drug Application Approvals by US FDA (1-15 June 2024)

New drug applications approved by US FDA as of 1-15 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Weekly tirzepatide works for weight loss in Chinese adults with obesity

Once-weekly treatment with tirzepatide at either 10 or 15 mg appears to yield substantial reductions in weight, according to data from the phase III SURMOUNT-CN trial.

Duodenal switch not necessarily better than RYGB for patients with high BMI

In the treatment of patients with a BMI of 50–60 kg/m2, duodenal switch (DS) appears to result in better weight loss outcomes but also more frequent adverse events, including nutritional complications, as compared with Roux-en-Y-gastric bypass (RYGB), according to an open-label study.

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

Treatment with olezarsen in patients with hypertriglyceridemia and elevated cardiovascular risk results in substantial reductions in triglyceride, apolipoprotein B, and non–high-density lipoprotein cholesterol levels, while having no major safety signals, according to data from the phase IIb Bridge–TIMI 73a study.

Gastric fundus ablation targets hunger hormone for weight loss

Ablating the gastric fundus to reduce the production of the hunger hormone ghrelin helps women curb their appetite and lose body weight in the ABLATE-WEIGHT first-in-human trial.

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

Glucose-lowering drugs such as the glucagon-like peptide-1 receptor agonist (GLP-1-RA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), and dipeptidyl peptidase-4 inhibitor (DPP-4i) work better and are more cost-effective than sulfonylureas and glinides (SU) as second-line treatment for type 2 diabetes (T2D), according to a population-based retrospective cohort study.

Low-carb diet eases pain, improves QoL in women with lipedema

Women with lipedema who lose weight through proper diet can see improvements in their quality of life (QoL), suggests a study. Specifically, an energy-restricted low-carbohydrate diet (LCD) appears to be better at pain reduction than a standard control diet.